Lexicon Pharmaceuticals (LXRX) Non-Current Deffered Revenue (2010 - 2019)

Lexicon Pharmaceuticals (LXRX) has 10 years of Non-Current Deffered Revenue data on file, last reported at $24.3 million in Q2 2019.

• Non-Current Deffered Revenue for Q2 2019 came in at $24.3 million, up 33.38% year-over-year; the trailing twelve-month figure through Jun 2019 was $24.3 million (up 33.38% YoY), and the FY2018 annual result was $23.7 million, down 5.03% from the prior year.
• Non-Current Deffered Revenue declined to $24.3 million in Q2 2019 per LXRX's latest filing, from $24.6 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $109.2 million in Q4 2015 and troughed at $11.7 million in Q1 2015.
• A 5-year average of $38.1 million and a median of $24.8 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2016 and 2017: Non-Current Deffered Revenue soared 777.17% in 2016, then tumbled 72.01% in 2017.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $109.2 million in 2015, then tumbled by 55.17% to $48.9 million in 2016, then sank by 49.11% to $24.9 million in 2017, then fell by 5.03% to $23.7 million in 2018, then increased by 2.61% to $24.3 million in 2019.
• Business Quant data shows LXRX's Non-Current Deffered Revenue at $24.3 million in Q2 2019, $24.6 million in Q1 2019, and $23.7 million in Q4 2018.